RxDoctor Payments Data

Antoni Berger, MD

Internal Medicine · Kensington, CTNPI 1356450258

Payments from drug & device makers

$936in general payments, 2019–2025

Across 55 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$246
  • Novo Nordisk$245
  • GSK$96
  • Pfizer$76
  • AstraZeneca$61
  • Kowa Pharmaceuticals America, Inc.$41
  • plus $170 from 8 others

What the payments were for

  • Food & beverage$87293%
  • Education$657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$936 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$31,492
Medicare patients
78
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$152,150
EliquisApixaban99$132,972
JardianceEmpagliflozin89$118,849
FarxigaDapagliflozin Propanediol56$56,446
LinzessLinaclotide52$45,570
MounjaroTirzepatide21$34,296
Breo ElliptaFluticasone/Vilanterol44$26,770
JanuviaSitagliptin Phosphate14$23,856
ProliaDenosumab14$23,631
XareltoRivaroxaban14$18,885
MyrbetriqMirabegron27$15,281
TrulicityDulaglutide12$13,634
Victoza 3-PakLiraglutide11$12,023
TradjentaLinagliptin17$11,564
Tresiba Flextouch U-200Insulin Degludec19$8,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$245$152,150100 claims
PfizerEliquis$76$132,97299 claims
Boehringer IngelheimJardiance, Tradjenta$27$130,413106 claims
AstraZenecaFarxiga$61$56,44656 claims
AbbVieLinzess, Synthroid$246$48,85588 claims
Lilly USA, LLCMounjaro, Trulicity$36$47,93033 claims
GSKBreo Ellipta$96$26,77044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Kensington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →